← All trials

NCT06840392

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Mar 12, 2025
Primary completion
Jun 2, 2028
Completion date
Oct 20, 2028
First posted
Feb 21, 2025
Last posted
Mar 10, 2025
Enrollment
555
Arms / groups
3 / —
Source
AACT · ctgov ingestion

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.